Nathan Rice

Stock Analyst at Piper Sandler

(3.16)
# 1,082
Out of 5,182 analysts
61
Total ratings
52.63%
Success rate
12.22%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $142.52
Upside: +5.25%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $43.58
Upside: +10.14%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $47.52
Upside: -11.62%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $33.34
Upside: +4.98%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $77.62
Upside: -4.66%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $158.42
Upside: -46.98%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $184.69
Upside: +6.67%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $24.11
Upside: -62.67%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $584.05
Upside: -25.52%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $272.60
Upside: -14.53%
Initiates: Neutral
Price Target: $83
Current: $37.26
Upside: +122.76%
Initiates: Overweight
Price Target: $15
Current: $21.61
Upside: -30.59%